The pharmaceutical industry has witnessed a resurgence of mergers and acquisitions (M&As) as companies seek to gain a competitive edge, accelerate innovation, and drive growth. By consolidating ...

Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...

Only 18% of payers report using RWE in coverage decisions despite 80% expressing demand, reflecting a market access disconnect driven primarily by interpretability and usability barriers. Payers’ ...

This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...

A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain and pricing risks. The US has opened a formal trade investigation into how ...

Capital is flowing into CGTs, while outpatient CAR-T delivery reached 45% in 2025, expanding the number of administration sites requiring specialized, time-critical logistics support. Maintaining vein ...

Patient support services—supported directly or indirectly by pharma companies—have gone from a ‘nice to have’ feature to a ‘must have’ one in recent years. The reasons are not hard to find: the growth ...

Market growth is propelled by high-cost specialty therapies, payer friction, and complex access pathways, making hub and patient support infrastructure increasingly central to commercialization and ...

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...

Intelliguard and Accucold have launched an RFID-enabled refrigerated cabinet to improve hospital medication tracking, visibility, and cold-chain control. AI-driven cold chain visibility is only as ...

DSCSA enforcement in 2025–2026 makes interoperable, package-level electronic traceability and saleable-returns verification a primary constraint; non-serialized, non-auditable architectures now create ...